The Effect of Semaglutide on Glycolipid Metabolism in Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease
Department of Endocrinology, Hulunbuir People’s Hospital, Hulunbuir Clinical Medical College, Inner Mongolia University for Nationalities, Hulunbuir, Inner Mongolia 021000, 1Department of Endocrinology, The Second Hospital Tianjin, Tianjin 300150, China
Shen Kun Liu, Department of Endocrinology, The Second Hospital Tianjin, Tianjin 300150, China, E-mail: firstname.lastname@example.org
The research was to investigate the effect of semaglutide on glycolipid metabolism in patients with both type 2 diabetes mellitus and non-alcoholic fatty liver disease. A total of 150 patients with both type 2 diabetes mellitus and non-alcoholic fatty liver disease admitted to our hospital from January 2020 to June 2020 were selected. They were divided into 2 groups using random number table, with 75 cases in each. The control group was treated with metformin hydrochloride tablets twice/d and 0.5 g/time, and the observation group was treated with semaglutide by hypodermic injection in the morning for a course of 3 mo. After 3 mo of treatment, both groups showed lower levels of 2 h postprandial blood glucose, fasting blood glucose, glycated hemoglobin A1c and homeostatic model assessment of insulin resistance, than before (all p<0.05), with distinctly lower levels in the observation group than in the control group. Fasting insulin levels in the observation group were significantly increased compared to that in the control group, with significant differences (p<0.05). Both groups showed decreased levels of triglyceride, total cholesterol and low-density lipoprotein cholesterol after treatment than before; with distinctly lower levels in the observation group than in the control group. After treatment, the level of high-density lipoprotein cholesterol in the observation group was higher than that in the control group. Both groups showed decreased levels of aspartate aminotransferase, alanine aminotransferase and gamma-glutamyl transpeptidase than before (p<0.05), with distinctly lower level in the observation group than in the control group. The observation group showed more significantly increased patients with mild result of color ultrasound and decreased patients with moderate to severe results than the control group. The treatment of semaglutide for patients with both type 2 diabetes mellitus and non-alcoholic fatty liver disease significantly alleviated the glycolipid metabolism and can significantly improve the fatty liver classification and the liver serum level of alanine aminotransferase, aspartate aminotransferase and gamma-glutamyl transpeptidase, which has considerable clinical application value.